Holen Sie sich die Stockscreener-App
169.38
1.09%
1.83
Handel nachbörslich:
170.01
0.63
+0.37%
Schlusskurs vom Vortag:
$167.55
Offen:
$169.1
24-Stunden-Volumen:
775.74K
Relative Volume:
1.32
Marktkapitalisierung:
$8.54B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-25.94
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
-5.21%
1M Leistung:
+16.64%
6M Leistung:
+50.76%
1J Leistung:
+105.14%
1-Tages-Spanne:
$168.51
$173.78
1-Wochen-Bereich:
$165.75
$179.02
52-Wochen-Spanne:
$79.19
$184.40
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
169.38 | 8.45B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-01 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Why Axsome Therapeutics Inc. stock is rated strong buyMarket Sentiment Indicators & You’ll Thank Yourself in 6 Months - bollywoodhelpline.com
Why Axsome Therapeutics Inc. stock could outperform in 20252025 Market Overview & Verified Chart Pattern Signals - ulpravda.ru
Will Axsome Therapeutics Inc. stock reach all time highs in 2025July 2025 Drop Watch & Daily Price Action Insights - ulpravda.ru
How interest rate cuts could boost Axsome Therapeutics Inc. stock2025 Pullback Review & Weekly Top Performers Watchlists - ulpravda.ru
Can Axsome Therapeutics Inc. (19X) stock hold up in economic slowdown2025 Historical Comparison & Expert Approved Momentum Ideas - ulpravda.ru
How Axsome Therapeutics Inc. stock reacts to Fed rate cutsBreakout Watch & Fast Gain Swing Alerts - ulpravda.ru
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Earns "Equal Weight" Rating from Morgan Stanley - MarketBeat
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - MarketBeat
Morgan Stanley Downgrades Axsome Therapeutics to Equal Weight From Overweight, Adjusts PT to $204 From $196 - MarketScreener
2 Healthcare Stocks to Buy for 2026 and Beyond - Finviz
Morgan Stanley downgrades Axsome stock after 23% rally, raises price target - Investing.com Canada
Axsome therapeutics CEO sells $23.8m in shares By Investing.com - Investing.com UK
Herriot Tabuteau Sells 78,703 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) CEO Sells 29,450 Shares of Stock - MarketBeat
Herriot Tabuteau Sells 31,261 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Equities Analysts Set Expectations for AXSM Q2 Earnings - MarketBeat
UBS Adjusts Price Target on Axsome Therapeutics to $248 From $163, Maintains Buy Rating - MarketScreener
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
H.C. Wainwright raises Axsome Therapeutics stock price target on FDA priority review - Investing.com Canada
Axsome Therapeutics (AXSM) Stock Analysis: Revenue Growth Soars Amid Biotech Innovations - DirectorsTalk Interviews
AXSM: HC Wainwright & Co. Raises Price Target to $200 and Mainta - GuruFocus
Stanley Laman Group Ltd. Makes New $2.13 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics - The Pharma Letter
Axsome Therapeutics Insider Sold Shares Worth $6,206,969, According to a Recent SEC Filing - MarketScreener
Why Axsome Therapeutics (AXSM) Is Up 17.5% After Dual FDA Boosts For AXS-05 And AXS-12 – And What's Next - Yahoo Finance
Axsome Therapeutics (AXSM): Reassessing Valuation After Key FDA Milestones for AXS-05 and AXS-12 - Yahoo Finance
Axsome therapeutics director Saad sells $6.2m in shares By Investing.com - Investing.com Canada
Mark Saad Sells 37,577 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Glaukos (GKOS) - The Globe and Mail
A Comprehensive Guide To Axsome: Unlocking The Potential Of Innovative Therapeutics- - shababeek.org
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation - Finviz
Truist Securities reiterates Buy rating on Axsome Therapeutics stock By Investing.com - Investing.com Canada
Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar? - Yahoo Finance
Deutsche Bank Raises Price Target on Axsome Therapeutics to $223 From $186, Keeps Buy Rating - MarketScreener
FDA grants Axsome’s AXS-05 sNDA priority review designation - The Pharma Letter
AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation - ts2.tech
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug - ts2.tech
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Praxis Precision Medicines (PRAX) - The Globe and Mail
Axsome Advances AXS-12 Toward NDA Filing for Narcolepsy - The Globe and Mail
Axsome (AXSM) Stock; Climbs Nearly 23% After FDA Accelerates Alzheimer’s Review - CoinCentral
Moody Aldrich Partners LLC Trims Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing - ts2.tech
Axsome wins FDA priority review for Auvelity in Alzheimer’s disease agitation - MSN
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review - ts2.tech
FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 By Investing.com - Investing.com Nigeria
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 - The Globe and Mail
Axsome Therapeutics Stock Skyrockets: What’s Next? - StocksToTrade
Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation - ts2.tech
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? - AOL.com
Key Takeaways - StocksToTrade
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):